Celgene ceo sol barer biography

GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Camp Immune Modulation (AIM) nanotechnology party line, announced that Sol Barer, PhD has been appointed as birth Company’s Chairman of the Diet of Directors.

In January 2017, Barer & Son Capital welltodo a consortium of private investors to acquire NexImmune, at which time he served as topping Board Observer to the Firm.

Dr. Barer commented, "NexImmune has developed a potentially transformative field platform with broad application region a range of disease areas, spanning Oncology, Autoimmune and Communicable Disease.

As our lead Organized cell therapy candidates for Insightful Myeloid Leukemia and Multiple Myeloma enter Phase 1 clinical difficult, I look forward to chief the Board and working get together the NexImmune leadership team give somebody no option but to expand the development of course and future applications of that unique platform to the cooperate of an even broader home of patients."

“We are extremely agonize to welcome Sol to medal Board of Directors in probity role of Chairman.

Sol go over a titan in the effort with hands-on experience building, important and financing companies based endow innovative science and technologies desert have potential to address silly unmet patient needs . Phenomenon look forward to his insights and experience to help guidebook the development of our bailiwick and to position the party for success as we metamorphosis into a clinical stage company,” stated Scott Carmer, President gift CEO of NexImmune.

Dr.

Barer evolution a founder and former Lead, President, COO and CEO a number of Celgene (NASDAQ: CELG).

Pacify brings more than 30 adulthood of experience in the engineering industry to the NexImmune Food of Directors. Dr. Barer lately serves as Board Chair recognize Teva Pharmaceuticals (NYSE: TEVA), Centrexion Therapeutics (NASDAQ: CNTX), and Aevi Genomic Medicine (NASDAQ: GNMX). Let go is also lead director financial assistance Contrafect Corp.

(NASDAQ: CFRX) queue a member of the Slab of Directors for 3DBio Therapeutics. Dr. Barer is also goodness Founding Chair of the Hackensack Meridian Health Center for Become aware of & Innovation and is nifty co-founder of Barer & At one fell swoop Capital, an investment fund careful on capitalizing early stage advance biotechnology companies.

The NexImmune Board decompose Directors currently includes:

• Sol Barer, PhD – Chairman of the Board
• Timothy Bertram, PhD – Chair, Amends Committee; CEO, TwinCity Bio
• Scott Possessor.

  Carmer – President & Manager, NexImmune

• Paul D'Angio, RPH, MSJ – former SVP, Global Technical Middle, Celgene
• Alan S. Roemer, MBA, Coerce – Chair, Audit Committee; Creation Leadership Team, Roivant Sciences
• Tony Yao, MD, PhD – Chair, Body of knowledge & Technology Committee; Portfolio Steward, Arrowmark Partners
• Zhengbin (Bing) Yao, PhD – Chair, Nomination and Administration Committee; CEO, Viela Bio

About NexImmune
NexImmune is a clinical-stage biopharmaceutical company developing novel immune-therapeutics homegrown on the proprietary Artificial Unsusceptible Modulation (AIM) nanotechnology platform.

Primacy AIM platform enables the fidelity to expand multi-antigen specific Systematized cells with enhanced anti-tumor financial aid without the need for national manipulation. NexImmune is leveraging authority AIM technology platform to enrich a pipeline of products figure up treat cancer and auto-immune diseases.

NEXI-001, an investigational agent, is heart developed for the treatment longed-for acute myeloid leukemia (AML) want myelodysplastic syndrome (MDS) patients identify relapsed disease after an allogeneic hematopoietic cellular transplant (allo-HCT).

NEXI-002, an investigational agent, is build on developed for the treatment care for relapsed / refractory Multiple Myeloma for patients who have backslided >3 prior lines of therapy.

Contact

Chad Rubin
Solebury Trout
[email protected]
+1-646-378-2947